- Home
- VATE vs BLRX Comparison
VATE vs BLRX Comparison
Compare VATE & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VATE | BLRX |
|---|---|---|
| Founded | 1994 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.8M | 12.6M |
| IPO Year | 1996 | 2010 |
Fundamental Metrics
Financial Performance| Metric | VATE | BLRX |
|---|---|---|
| Price | $11.97 | $2.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 88.5K | 8.2K |
| Earning Date | 05-14-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,246,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.55 | N/A |
| 52 Week Low | $3.75 | $2.15 |
| 52 Week High | $21.30 | $4.56 |
Technical Indicators
Market Signals| Indicator | VATE | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 29.56 | 44.80 |
| Support Level | $4.38 | $2.65 |
| Resistance Level | $13.40 | $3.02 |
| Average True Range (ATR) | 0.74 | 0.17 |
| MACD | 0.14 | -0.00 |
| Stochastic Oscillator | 9.86 | 37.05 |
Price Performance
Historical ComparisonAbout VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.